Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

AMLX Amylyx Pharmaceuticals Inc

1,87

-0,02 (-1,06%)

Vor Marktöffnung

Zuletzt aktualisiert: 13:45:25

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Amylyx Pharmaceuticals Charts.

Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Amylyx Pharmaceuticals Charts.

News Amylyx Pharmaceuticals Inc

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 9 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
Donnerstag 9 Mai 2024 (1 Tag vor) • Business Wire

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
Mittwoch 8 Mai 2024 (2 Tage vor) • Business Wire

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Donnerstag 2 Mai 2024 (1 Woche vor) • Business Wire

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Mittwoch 10 April 2024 (4 Wochen vor) • Business Wire

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX
Dienstag 9 April 2024 (1 Monat vor) • PR Newswire (US)

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
Montag 8 April 2024 (1 Monat vor) • Business Wire

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX
Freitag 5 April 2024 (1 Monat vor) • PR Newswire (US)

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Donnerstag 4 April 2024 (1 Monat vor) • Business Wire

The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX
Dienstag 2 April 2024 (1 Monat vor) • PR Newswire (US)

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders
Freitag 29 März 2024 (1 Monat vor) • PR Newswire (US)

Weitere Amylyx Pharmaceuticals Inc News-Artikel

Financial Select Sector

BNP Paribas (QX)

Energy Select Sector SPDR

Invesco QQQ Trust Series 1

Deutsche Lufthansa

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen